FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 361 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Shannen Doherty Opens Up About Life After Cancer And BH90210 August 16, 2019 Cancer waiting times: Latest updates and analysis May 11, 2023 FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients June 23, 2020 Trastuzumab Deruxtecan in Second-Line Treatment for Patients with HER2-positive Advanced Gastric... July 5, 2023 Load more HOT NEWS ctDNA-Guided Treatment Influence on Survival in Advanced NSCLC Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors New analysis estimates over 21 million UK adults will be obese... Allergan Recalls Textured Breast Implants Worldwide Due To Cancer Risk At...
